Abcam, ab278103, Anti-FRA1 antibody [EPR23767-177] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal FRA1 antibody. Carrier free. Suitable for ICC/IF, IP, WB, Flow Cyt (Intra) and reacts with Human, Mouse samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23767-177,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Human,
Applications:ICC/IF, WB, Flow Cyt (Intra), IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab278103 is the carrier-free version of
ab252421
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FRA1 also known as FOS-like antigen 1 (FOSL1) is a transcription factor and a part of the AP-1 complex. It weighs about 45 kDa. This protein regulates gene expression linked to cell proliferation differentiation and survival. FRA1 shows expression in various tissues particularly in those undergoing rapid growth and development. The protein mediates immediate early gene response to diverse stimuli.
Biological function summary
In various settings FRA1 serves a role in regulating cellular responses to external signals. It forms a heterodimer with members of the JUN family to create the transcription factor AP-1 complex active in cell cycle regulation and signal transduction. This complex modulates expression of genes involved in processes like hematopoiesis and angiogenesis demonstrating its importance in physiological development and maintenance.
Pathways
The involvement of FRA1 in cellular signaling cascades stands out notably in the MAPK/ERK pathway. This pathway plays a significant role in cell growth and differentiation with FRA1 acting alongside other proteins like ERK to relay signals from surface receptors to the nucleus. Also FRA1 influences the Wnt signaling pathway which impacts cell fate decisions and embryonic development via its interactions and regulatory functions.
Researchers associate FRA1 expression with certain cancers including lung and breast cancer due to its role in controlling cell proliferation and invasion. In cancer FRA1 interacts with proteins like JUN which partner in transforming normal cells into malignant ones through the dysregulation of AP-1 activity. Its role in metastasis highlights FRA1 as a potential biomarker or therapeutic target in oncology.